Dr. Bowles is an Instructor at the Icahn School of Medicine at Mount Sinai in New York, USA, where her research focus is understanding the mechanisms underlying the development of different tauopathies, including Alzheimer’s disease (AD), Progressive supranuclear palsy (PSP) and Frontotemporal dementia (FTD). She integrates genetics, induced pluripotent stem cell models and biochemical approaches to study these diseases. Her specific interests include understanding how structural and genetic variation across the 17q21.31 (MAPT) locus contributes to increased risk for both PSP and Parkinson’s disease, how different cell types are affected by this variation, and how this region differs structurally between different ancestries. She also studies how dysregulation of MAPT splicing influences different neuropathological features of tauopathies, and how this differs between diseases. Dr. Bowles is a member of the Tau consortium stem cell group, in which her role includes bulk and single cell transcriptomic analysis of MAPT mutation organoids, with the aim to uncover prodromal mechanisms underlying susceptibility to tauopathy.
Kathryn Bowles, PhD
First published on: November 08, 2021
Last modified on: December 24, 2024